nephropathy
Novartis’ $3.2B Chinook Investment Soars with Successful Phase 3 Endpoint, Paving the Way for 2024 FDA Filing
Anika Sharma
Novartis is seeing promising results from its substantial $3.2 billion investment in Chinook Therapeutics. Exciting top-line data from a phase ...
Omeros halts phase 3 trial of kidney disease drug after disappointing results, stock plummets
Anika Sharma
In a surprising turn of events, Omeros has halted its phase 3 trial of narsoplimab in kidney disease patients, as ...
